12-Month Lobbying Summary - In-house Corporation

• Subject matter details in previous versions

  Details Regarding the Identified Subject Matter

  Subject matters	Details	Categories
  Subject matters were not required to be associated with subject matter details when this content was submitted	Acts that propose to amend the Food and Drug Act and amendments to the Food and Drug Regulations related to the regulation of pharmaceuticals, biologic therapies, medical devices and foods.	Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Canada's Drug and Health Technology Agency (CADTH) and the pan Canadian Pharmaceutical Alliance (pCPA), with respect to value assessment and public formulary listing of new medicines.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Common Drug Review (CDR), with respect to health economics assessment and recommendations made on new medicines.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Communications regarding a national pharmacare program and Canada Drug Agency.	Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Communications regarding national pharmacare legislation, regulations, policies or programs.	Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Communications regarding the value assessment of new medicines by the Canadian Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Communications with Health Canada regarding guidelines for pediatric action plans.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials.	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Communications with Health Canada regarding the application of its nitrosamine guidelines.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products.	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Communications with Heath Canada regarding modernization of the medical devices regulatory framework.	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Implementation of Patented Medicine Notice of Compliance (PMNOC) Regulations and Patent Term Adjustment regime, as this relates to intellectual property protection of prescription drugs.	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Innovation, Science and Economic Development Canada (PMNOC) Regulations, as this relates to regulating intellectual property of prescription drugs; as well as discussions pertaining to growth and development of the life sciences industry in Canada, including as part of an Innovation Agenda.	Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Patented Medicine Prices Review Board (PMPRB) Regulations. with regard to prices charged by patentees for patented medicines sold in Canada.	Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Pharmaceutical intellectual property proposals that are part of the Comprehensive Economic and Trade Agreement with the European Union.	Legislative Proposal, Bill or Resolution, Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Public Health Agency of Canada, regarding the federal response to the hepatitis C virus.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Similar Entry Biologics (SEBs): requiring a Health Canada regulatory framework that support the approval of SEBs	Legislative Proposal, Bill or Resolution, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.	Policies or Program

  Subject matters in previous versions

  • Aboriginal Affairs
  • Budget
  • Economic Development
  • Federal-Provincial Relations
  • Health
  • Industry
  • Intellectual Property
  • International Trade
  • Research and Development
  • Science and Technology
  • Taxation and Finance

Government Institutions

• Atlantic Canada Opportunities Agency (ACOA)
• Canadian Institutes of Health Research (CIHR)
• Correctional Service of Canada (CSC)
• Employment and Social Development Canada (ESDC)
• Finance Canada (FIN)
• Global Affairs Canada (GAC)
• Health Canada (HC)
• House of Commons
• Immigration and Refugee Board (IRB)
• Indigenous Services Canada (ISC)
• Innovation, Science and Economic Development Canada (ISED)
• Intergovernmental Affairs Secretariat (IGA)
• Invest in Canada Hub
• National Defence (DND)
• National Research Council (NRC)
• Patented Medicine Prices Review Board (PMPRB)
• Prime Minister's Office (PMO)
• Privy Council Office (PCO)
• Public Health Agency of Canada (PHAC)
• Public Services and Procurement Canada (PSPC)
• Royal Canadian Mounted Police (RCMP)
• Senate of Canada
• Treasury Board Of Canada Secretariat (TBS)
• Veterans Affairs Canada (VAC)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

• Written communication
• Oral communication
• Arrange one or more meetings

Senior Officers whose lobbying activities represent less than 20% of their Duties

• RAMI FAYED, Vice President and General Manager, Canada | No public offices held
• Stephane Barakat, Head, Market Access & HEOR, Oncology | No public offices held
• Christine Eleia, Head, Market Access & HEOR, Immunology | No public offices held
• Caroline Jacques, Senior Counsel, Canada | No public offices held
• Thula Kanagenthiran, Head, Market Access & HEOR, Specialty | No public offices held
• Corry McElrea, Head, Field Market Access & Government Affairs | No public offices held
• Amber McLeod, Lead, Regulatory Affairs | No public offices held
• Judith Mergl, Director, Regulatory Affairs | No public offices held
• Steve Popp, Head, Strategic Pricing & Contracting | No public offices held
• Stephanie Sauvageau, Head, Medical Affairs | No public offices held
• Arima Ventin, Executive Director, Market Access and Government Affairs | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

• Sara Chahab, Field Lead, Market Access & Government Affairs - Immunology | No public offices held
• Adam Cook, Manager, Market Access and Government Affairs, Ontario & Federal Programs | No public offices held
• Catherine Desjardins, Field Lead, Market Access & Government Affairs - Oncology | No public offices held
• Lauren Fischer, Lead, Government Affairs & Policy | No public offices held
• Harold Just, Manager, Market Access and Government Affairs - Oncology | No public offices held
• David Link, Field Lead, Market Access & Government Affairs - Specialty | No public offices held
• Claude Longpre, Manager, Government Affairs, Quebec | No public offices held
• Eric Pegolo, Manager, Market Access and Government Affairs, Ontario | No public offices held

• Lobbyists in previous versions

  Senior Officers whose lobbying activities represent less than 20% of their Duties

  • Kevin Bernard, Manager, Government Affairs & Policy | Designated public offices held
  • Adam Cook, Manager, Market Access and Government Affairs, Ontario & Federal Programs | No public offices held
  • David Link, Regional Manager Market Access & Government Affairs | No public offices held
  • Christina Pelizon, Medical Director | No public offices held
  • Tracey Ramsay, Vice President and General Manager, AbbVie Canada | No public offices held
  • Catherine Robert, Senior Manager, Market Access and Health Economics | No public offices held

  Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

  • David Link, Regional Manager Market Access & Government Affairs | No public offices held
  • Steve Popp, Lead, Pricing & Contracting | No public offices held
  • Dale Yakutchik, Manager, Market Access and Government Affairs, Atlantic | No public offices held
  • Dale Yakutchik, Provincial Affairs Manager, Atlantic | No public offices held